RET-IN-1 manufacturers
- LOXO-292
-
- $90.00
-
2026-05-05
- CAS:2222755-14-6
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
|
| | RET-IN-1 Basic information | | Uses |
| Product Name: | RET-IN-1 | | Synonyms: | RET-IN-1;Pyrazolo[1,5-a]pyridine-3-carbonitrile, 4-[5-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-2-pyrazinyl]-6-[(2R)-2-morpholinylmethoxy]-;RET IN 1,RETIN1;selpercatinib(LOX0292);Compound T16735 | | CAS: | 2222755-14-6 | | MF: | C29H31N9O3 | | MW: | 553.61 | | EINECS: | | | Product Categories: | | | Mol File: | 2222755-14-6.mol |  |
| | RET-IN-1 Chemical Properties |
| density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). | | solubility | Soluble in DMSO | | pka | 8.23±0.40(Predicted) | | form | solid | | InChIKey | GTQISTQEBXXLPC-UBVWURDFSA-N | | SMILES | C12=C(C#N)C=NN1C=C(OC[C@@H]1OCCNC1)C=C2C1=NC=C(N2CC3CC(N3CC3=CC=C(OC)N=C3)C2)N=C1 |
| | RET-IN-1 Usage And Synthesis |
| Uses | Serpatinib (LOXO-292) is a potent, orally administered, highly selective transfection rearrangement (RET) kinase inhibitor used to treat cancer patients with RET abnormalities. The RET gene is a proto-oncogene that undergoes rearrangement during transfection, hence its name. This gene encodes a cell membrane receptor tyrosine kinase, and its abnormalities are a rare driver of many types of tumors. | | Description | RET-IN-1 is an oral and selective investigational drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. |
| | RET-IN-1 Preparation Products And Raw materials |
|